BIOMERICA ANNOUNCES SECOND QUARTER FINANCIAL RESULTS
-Sales up over 39% for the Quarter, Over 29% for first 6
months-
IRVINE, California, January 18, 2012 - OTC BB: BMRA) today reported net sales of $1,616,606 for the three months ended November 30, 2011, compared to $1,160,842 for the same period in the previous year, an increase of $455,764, or 39.3%. Net sales were $3,024,271 for the first six months of fiscal 2012 compared to $2,338,554 for the first six months in fiscal 2011, an increase of $685,717 or 29.3%.
Biomerica announced net income for the three months ended November 30, 2011, of $195,092 or $0.03 per share versus a net income of $137 or $0.00 per share in the previous fiscal year during the same quarter. The net income for the six months ended November 30, 2011 was $312,884 or $0.05 per share, compared to net loss of $12,049 or $0.00 per share in the same period the previous fiscal year.
"While we are pleased with the continued sales gains and financial progress made in the quarter, we are working diligently to expanding our distribution and product offering during this fiscal year," stated Zackary Irani, Biomerica CEO. "Our outlook remains positive for the remainder of the year."
About Biomerica (OTCBB: BMRA)
) is a global biomedical company that develops, manufactures
and markets advanced diagnostic products used at the
point-of-care (in home and in physicians' offices ) and
in hospital/clinical laboratories for the early detection of
medical conditions and diseases. The Company's
products are designed to enhance the health and well being of
people, while reducing total healthcare costs.
Biomerica primarily focuses on products for Diabetes,
Gastrointestinal Disease and esoteric testing.
The Private Securities Litigation Reform Act of 1995 provides
a "safe harbor" for forward-looking statements. Certain
information included in this press release (as well as
information included in oral statements or other written
statements made or to be made by Biomerica) contains
statements that are forward-looking; such as statements
relating to intended launch dates, sales potential,
significant benefits, market size, growth prospects, new
products, favorable outlook, new distributors, expansion,
increases in productivity and margins, expected orders,
leading market positions, anticipated future revenues or
production volume of the Company, the launch or success of
product and new product offerings. Such forward-looking
information involves important risks and uncertainties that
could significantly affect anticipated results in the future,
and accordingly, such results may differ materially from
those expressed in any forward-looking statements made by or
on behalf of Biomerica. The potential risks and uncertainties
include, among others, fluctuations in the Company's
operating results due to its business model and expansion
plans, downturns in international and or national economies,
the Company's ability to raise additional capital, the
competitive environment in which the Company will be
competing, and the Company's dependence on strategic
relationships. The Company is under no obligation to update
any forward-looking statements after the date of this
release.
distribué par | Ce noodl a été diffusé par Biomerica Inc. et initialement mise en ligne sur le site http://www.biomerica.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-18 20:17:33 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |